Observational Study of Blood Biomarkers for Pancreatic Cancer
This study is looking for ways to find pancreatic cancer early and see how well treatments are working. Researchers are collecting blood, tumor tissue, and cyst fluid samples to find specific markers (biomarkers) that could help diagnose pancreatic cancer sooner. You might be able to join if you have pancreatic cancer, other pancreatic conditions, or cysts, are at least 18 years old, and meet other health criteria like a hemoglobin level above 8. The main goal is to see how well these biomarkers can identify early-stage pancreatic cancer, with results expected in four years. The study is currently unclear on its recruitment status.
- Study design
- This is an observational study aiming to enroll 120 participants. It is not a treatment study, but rather collects samples to understand pancreatic cancer better.
- What's involved
- If you participate, you may have up to 50ml of blood drawn. Tumor tissue and cyst fluid will be collected from biopsies already planned as part of your care.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study aims to measure changes in biomarkers to determine sensitivity and specificity for diagnosing early-stage pancreatic cancer over 4 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT03334708
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
Recruiting
Not specifiedAges 18+ObservationalMemorial Sloan Kettering Cancer CenterInvestigator-initiated
~120 participants
Updated 2026-08-14 on ClinicalTrials.gov
What's tested:Blood DrawTumor Tissue CollectionCyst Fluid
At a glance
Recruiting sites
8 of 13 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in biomarkers to determine sensitivity and specificity of the assay to diagnose early stage pancreatic cancer
Measured over 4 years
Conditions
Where it's being run
13 sites across 3 statesNew York8
Israel3
New Jersey2
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Radiological, histological or cytological confirmed diagnosis of locally advanced or metastatic pancreatic adenocarcinoma by the enrolling institution
Patient planning to receive systemic treatment
Hemoglobin \> 8
ECOG performance status 0-2
A minimum age of 18 years old
Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).
Radiological, histological or cytological confirmed diagnosis of pancreatic adenocarcinoma by the enrolling institution
Patient planned to undergo upfront resection
No pre-operative systemic therapy nor chemoradiation therapy planned
Hemoglobin \> 8
ECOG performance status 0-2
A minimum age of 18 years old
Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).
Confirmed diagnosis of acute pancreatitis or other acute pancreatic pathology by the enrolling institution
Hemoglobin \> 8
ECOG performance status 0-2
A minimum age of 18 years old
Confirmed diagnosis of chronic pancreatitis or other non-cystic chronic pancreatic pathology by the enrolling institution
Hemoglobin \> 8
ECOG performance status 0-2
A minimum age of 18 years old
Confirmed diagnosis of IPMN without high risk features by the enrolling institution
A minimum age of 18 years old
Confirmed diagnosis of benign pancreatic cyst by the enrolling institution
A minimum age of 18 years old
A minimum age of 18 years old
Exclusion
Prior chemotherapy or radiation therapy for pancreatic cancer within the last 3 months in the localized setting
Active second malignancy, unless low grade malignancy
Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
Neoadjuvant chemotherapy or radiation therapy is planned
Active second malignancy, unless low grade malignancy
Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
Active or prior malignancy, except prior non-melanoma skin cancer
Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
Active or prior malignancy, except prior non-melanoma skin cancer
Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
IPMN with high risk features or planned resection
Active or prior malignancy, except prior non-melanoma skin cancer
Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
Active or prior malignancy, except prior non-melanoma skin cancer
Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
Active or prior malignancy, except prior non-melanoma skin cancer
Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
What this trial measures
- Change in biomarkers to determine sensitivity and specificity of the assay to diagnose early stage pancreatic cancer4 years